Facilitating More OTC Switches In US Graduates To Regulatory Plan On FDA’s Unified Agenda
Fall 2021 Update Also Includes OTC Hearing Aid, Drug Co-Packaging, IND Exemption Timelines
For first time rules for novel switches and OTC hearings aids are parts of “significant regulatory actions” in agency’s plans. Information is added in Unified Agenda items explaining likely benefits and costs from the changes.
You may also be interested in...
In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.
Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.
Responding to Sen. Roger Marshall’s question on rulemaking to accelerate OTC switches by allowing NDA sponsors to use extra-label information to guide consumers through self-selection of a drug, Robert Califf said he’d support making progress on a proposal FDA began considering in 2012 in its NSURE initiative.